Invest In Litigation Funding
Tort Fund offers collateralized, UCC1-secured investments to investors seeking high yield with social impact 
Invest In Litigation Funding
Tort Fund offers collateralized, UCC1-secured investments to investors seeking high yield with social impact 
Why invest in legal claims?
Social Impact
Focus a portion of your portfolio on social impact investing and make a difference
Built-In Diversification
Invest in a broad range of cases that our underwriters believe will have a high probability of success
New Asset Class
Tap into the undercapitalized $200 billion U.S. litigation market
Why invest in legal claims?
Social Impact
Focus a portion of your portfolio on social impact investing and make a difference
Built-In Diversification
Invest in a broad range of cases that our underwriters believe will have a high probability of success
New Asset Class
Tap into the undercapitalized $200 billion U.S. litigation market
Tort Fund Investment Process
Accredited investors are eligible to make social impact investments in Tort Fund.

1
Apply
Review our investment materials and get verified
2
Fund
Sign investment documents and submit your funds to Tort Fund
3
Follow
Login to track when cases are settled and loans are repaid
4
Earn
Tort Fund will then distribute profits to shareholders
Recent investment offerings
Tort Fund investors are allocating a portion of their portfolios toward social impact investing
RoundUp Weed Killer
13,000+ Cases
Monsanto's Roundup, the most widely used herbicide in the world, may cause cancer. Farmers, gardeners, and other agricultural laborers diagnosed with non-Hodgkin's lymphoma are plaintiffs in over 13,000 cases already filed. Juries in the first three cases have awarded plaintiffs over $2 BILLION in compensatory and punitive...
Talcum Baby Powder
Over $5 BILLION
Talc products like Johnson's Baby Powder may increase the risk of ovarian cancer and/or mesothelioma (lung cancer). There are currently 14,200 lawsuits pending against Johnson & Johnson and juries have awarded over $5 BILLION to plaintiffs...
IVC Blood Clot Filters
10,000+ Cases
Inferior vena cava (IVC) filters are designed to keep blood clots from reaching the heart and lungs, but they can migrate, fracture, and puncture the inferior vena cava. Over 12,000 lawsuits are pending against two manufacturers and some cases have already been settled while a jury awarded $3.6 MILLION to the first plaintiff...
Start investing with Tort Fund
Diversify your portfolio with investments that deliver aggressive returns while hedging against economic volatility. 
Start investing with Tort Fund
Diversify your portfolio with investments that deliver aggressive returns while hedging against economic volatility. 
Contact | Privacy Policy | Terms of Use | Customer Service (888) 460-TORT
Contact | Privacy Policy | Terms of Use | Login 
Customer Service (888) 460-TORT
IMPORTANT MESSAGE: www.Tort Fund.com (the “Site”) is a website owned and operated by Tort Fund, LLC. (“Tort Fund”). By accessing this Site and any pages on this Site, you agree to be bound by its Terms of Use and Privacy Policy, as may be amended from time to time without notice or liability. Investment opportunities posted on the Site are indirect investments in legal claims offered through single purpose pooled investment funds managed by Tort Fund LLC. Tort Fund is not an investment advisor, broker-dealer or crowdfunding portal and does not engage in any activities requiring any such registration. The securities offerings posted on the Site are available to Accredited Investors only.
 
All accredited investors using the Site must acknowledge the speculative nature of these investments and accept the high risks associated with investing in legal claims including but not limited to concentration risk, lack of control over the prosecution of underlying claims and claimant's inability to assert and collect on their claims. Investment opportunities posted on this Site are “private placements” of securities that are not publicly traded, are subject to holding period requirements, and are intended for investors who do not need a liquid investment. The plaintiff may not prevail in their lawsuit, resulting in a loss of invested capital for investors. Investors must be able to afford the loss of their entire investment without a change to their lifestyle. The securities are offered pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended, and are not required to comply with specific disclosure requirements that apply to registration under the Securities Act. Neither the US Securities and Exchange Commission nor any state regulator or other regulatory body has passed upon the merits of or given its approval to the securities, the terms of the offerings, or the accuracy or completeness of any offering materials. Neither Tort Fund nor any of its directors, officers, employees, representatives, affiliates or agents shall have any liability whatsoever arising, for any error or incompleteness of fact or opinion in, or lack of care in the preparation or publication, of the materials and communication herein or the or that the valuation of any securities offering is appropriate. Tort Fund does not give investment advice, provide analysis or recommendations regarding any offering posted on the Site. Prior results are not indicative of future performance; actual results may vary materially. The Site may contain “forward looking statements” which are not guaranteed. All investors should make their own determination of whether or not to make any investment, based on their own independent evaluation and analysis. You are strongly advised to consult your legal, tax and financial advisors before investing. The securities offered on this Site can only be marketed in jurisdictions where public solicitation of offerings are permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

Learn more about investing in private placements from the SEC, FINRA or Tort Fund’s specific financing model.

© 2019 Tort Fund, Inc. All rights reserved.